December 2020

Allogene Therapeutics (NASDAQ: ALLO)

  • Pioneer in allogeneic cell therapies for cancer
  • Advanced 3 "off the shelf" CAR T programs to human clinical trials and initiated the industry’s first Phase II allogeneic trial
Allogene.com